Therefore, we tested if canagliflozin may stimulate AMPK, Akt and eNOS—critical signaling pathways that were reported to underlie protective effects in various cardiovascular diseases including myocardial IRI and infarction 12. The gene discussed is AKT1; the disease is cardiovascular disorder.